Journal Mobile Options
Table of Contents
Vol. 10, No. 1-4, 2012
Issue release date: April 2012
Neurodegenerative Dis 2012;10:187–190
(DOI:10.1159/000335909)

Prevalence and Profile of Mild Cognitive Impairment in Parkinson’s Disease

Monastero R. · Di Fiore P. · Ventimiglia G.D. · Ventimiglia C.C. · Battaglini I. · Camarda R. · Camarda C.
Laboratory of Epidemiology and Psychology of Aging and Dementia (LEPAD), Department of Experimental Biomedicine and Clinical Neuroscience (BioNeC), University of Palermo, Palermo, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: The frequency of mild cognitive impairment (MCI) in Parkinson’s disease (PD) ranges from 19 to 40%, and this is probably due to methodological differences between the studies. The aim of this study was to evaluate the frequency and profile of MCI in a large sample of nondemented PD subjects and neurologically healthy subjects (NHS). Methods: A total of 872 subjects (582 controls and 290 PD) were included. The association between MCI and PD was tested, using logistic regression models; odds ratios (OR) with 95% confidence intervals (CI) were calculated. Results: Fifty-three percent of PD subjects and 45% NHS met the criteria for MCI (p = 0.001). The PD subjects showed a higher frequency of nonamnestic MCI (naMCI), compared to NHS (23.8 vs. 14.4%, p ≤ 0.0001). In comparison to NHS, PD was associated with a univariate OR of 1.9 (95% CI = 1.3–2.8) for naMCI, and this association was marginally significant after multiple comparisons (multivariate OR = 1.5, 95% CI = 0.96–2.3, p = 0.077). Conclusion: The association between PD and the impairment of nonmemory domains is probably due to frontal-subcortical involvement, which characterizes the disease.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Mariani E, Monastero R, Mecocci P: Mild cognitive impairment: a systematic review. J Alzheimers Dis 2007;12:23–35.
  2. Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183–194.
  3. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M: Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;75:1062–1069.
  4. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, MizunoY, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M: Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007;22:2314–2324.
  5. Beyer MK, Janvin CC, Larsen JP, Aarsland D: A magnetic resonance imaging study of patients with Parkinson’s disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007;78:254–259.
  6. Hoehn MM, Yahr MD: Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–442.
  7. Hughes AJ, Daniel SE, Blankson S, Lees AJ: A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993;50:140–148.
  8. Fahn S, Marsden CD, Calne DB, Goldstein M (eds): Recent Developments in Parkinson’s Disease. Florham Park, Macmillan Health Care Information 1987, vol 2, pp 153–163.
  9. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-IV (Text Revision). Washington, American Psychiatric Association, 2000.
  10. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  11. Carlesimo GA, Caltagirone C, Gainotti G: The Mental Deterioration Battery: normative data, diagnostic reliability and quantitative analyses of cognitive impairment. Eur Neurol 1996;36:378–384.
  12. Spinnler H, Tognoni G, Italian Group on the Neuropsychological Study of Ageing: Italian standardization and classification of neuropsychological tests. Ital J Neurol Sci 1987;6(suppl 8):1–120.
  13. Luzzatti C, Willmes K, De Bleser R, Bianchi A, Chiesa G, De Tanti A, Gonella ML, Pozzoli C: New normative data for the Italian version of the Aachen Aphasia Test (AAT). Arch Psicol Neurol Psichiatria 1994;55:1086–1131.
  14. Giovagnoli AR, Del Pesce M, Mascheroni S, Simoncelli M, Laiacona M, Capitani E: Trail making test: normative values from 287 normal adult controls. Ital J Neurol Sci 1996;17:305–309.
  15. Basso A, Capitani E, Laiacona M: Raven’s coloured progressive matrices: normative values on 305 adult normal controls. Funct Neurol 1987;2:189–194.
  16. Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML, Forapani E, Russo A, Nichelli P: The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 2005;26:108–116.
  17. Warrington EK, James M: The Visual Object and Space Perception Battery. Bury St. Edmunds, Thames Valley Test Company, 1991.
  18. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240–246.
  19. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566–572.
  20. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW: Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914–919.
  21. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179–186.
  22. Parmelee PA, Thuras PD, Katz IR, Lawton MP: Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995;43:130–137.
  23. Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361–370.
  24. Foltynie T, Brayne CE, Robbins TW, Barker RA: The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain 2004;127:550–560.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00